Enveric Biosciences Announces \$13.9 Million Private Placement Financing

Key Highlights from the Announcement

• Private Placement Details: Enveric Biosciences, Inc. (NASDAQ: ENVB) has entered into definitive agreements to raise up to \$13.9 million through a private placement priced at-the-market under Nasdaq rules.
• Immediate Capital Injection: The company will receive approximately \$5 million upfront from the sale of 2,222,223 shares of common stock (or pre-funded warrants in lieu thereof) at \$2.25 per share, together with accompanying Series I and Series J warrants.
• Potential Additional Proceeds: The placement includes Series I and short-term Series J warrants, both exercisable immediately at \$2.00 per share. If fully exercised on a cash basis, these warrants could bring in an additional \$8.9 million.
• Warrant Expiry: The Series I warrants expire five years after the effective date of the resale registration statement, while Series J warrants have an eighteen-month expiry from that date.
• Placement Agent: H.C. Wainwright & Co. is the exclusive placement agent for this offering.
• Use of Proceeds: Net proceeds are intended for product development, working capital, and general corporate purposes.

Important Information for Shareholders

• Dilution: The offering will result in the issuance of a significant number of new shares and warrants, which may dilute existing shareholders’ holdings.
• Exercise of Warrants: There is no guarantee all warrants will be exercised; thus, the full \$13.9 million may not be realized.
• Regulatory Status: The securities are being offered in a private placement and are not registered under the Securities Act. The company has agreed to file one or more registration statements with the SEC to cover the resale of the unregistered securities.
• Potential for Share Price Movement: The financing strengthens Enveric’s balance sheet and provides runway for further development, but the potential dilution and the fact that the offering is priced close to the market could impact near-term share price valuation.
• Forward-Looking Risks: The company warns of several operational and regulatory risks, including the ability to complete the offering, successful clinical development, securing regulatory approvals, and the need for future funding. There is no guarantee of successful outcomes in these areas.

Company Overview

Enveric Biosciences is a clinical-stage biotechnology company developing next-generation, small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. Its lead candidate, EB-003, is the first compound designed to selectively engage both 5-HT 2A and 5-HT 1B receptors, aiming to deliver fast-acting, durable antidepressant and anxiolytic effects without hallucinogenic side effects. The company leverages a differentiated drug discovery platform and a growing library of patent-protected chemical structures.

Forward-Looking Statements & Risks

The press release contains forward-looking statements, including expectations about the closing of the offering, the potential exercise of warrants, the use of proceeds, and the execution of Enveric’s clinical and business strategies. Actual results may differ materially due to various factors such as clinical trial success, regulatory approvals, ability to secure future funding, and market developments.

Investors should review the company’s filings with the SEC, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, for a detailed discussion of risks and uncertainties.

Investor & Media Contacts

• Investor Relations:
  Tiberend Strategic Advisors, Inc.
  David Irish
  (231) 632-0002
  [email protected]
• Media Relations:
  Tiberend Strategic Advisors, Inc.
  Casey McDonald
  (646) 577-8520
  [email protected]

Disclaimer: This article is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. All investments carry risk, including the risk of loss. Investors should perform their own due diligence and consult with a professional advisor before making investment decisions. The information herein is based on a company press release and may contain forward-looking statements subject to significant risks and uncertainties.

View Enveric Biosciences, Inc. Historical chart here